Mablytics, Inc.
Research - New York, New York, United States
Mablytics, Inc. Employees
Mablytics, Inc. Senior Management
Mablytics, Inc. Details
Mablytics is a preclinical-stage biotechnology company developing immunotherapies directed at a novel target for the treatment of hematological and squamous cell cancers. MablT1 is a unique member of a family of receptors that has been shown to be over-expressed in epithelial cancers, and more recently on AML blasts. Current AML targets, including CD33, suffer from dose-limiting toxicities due to expression on hematopoietic stem and progenitor cells. MablT1 is not expressed on hematopoietic stem or progenitor cells supporting the rationale for the development of a safer AML immunotherapy.
Website:
http://www.mablytics.com
Employees:
4
HQ:
Location:
New York, New York, United States
Revenue: